Showing results (121-130 of 1,983) with videos related to
Sort By:
Pageof 199
Cancer Biology & Therapy|February 23, 2012
Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxelWeihong Zhao, Yongmei Song, Binghe Xu, et al.Journal of Personalized Medicine|February 25, 2023
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyZhijun Li, Yiqun Han, Jiayu Wang, et al.Cancer Management and Research|June 20, 2019
Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysisYiqun Han, Jiayu Wang, Weiming Liu, et al.Cancer Medicine|April 8, 2022
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patientsBinliang Liu, Zongbi Yi, Yanfang Guan, et al.Oncotarget|July 16, 2016
SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancerAnjie Zhu, Peng Yuan, Feng Du, et al.BMC Cancer|October 18, 2024
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II studyJiaxuan Liu, Maiyue He, Mingxia Jiang, et al.Future Oncology (London, England)|July 21, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutationXi Chen, Lei Ji, Ying Fan, et al.International Journal of Cancer|February 4, 2018
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han populationBo Lan, Fei Ma, Xiaoyu Zhai, et al.Breast (Edinburgh, Scotland)|April 27, 2020
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkersZongbi Yi, Binliang Liu, Xiaoying Sun, et al.Frontiers in Oncology|October 24, 2022
Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapyXiaoyan Qian, Meng Xiu, Qing Li, et al.Pageof 199